NOTTINGHAM, England--(BUSINESS WIRE)--The Board of Scancell Holdings plc (‘Scancell Holdings’ or the ‘Company’), (PLUS:SCLP), the developer of therapeutic cancer vaccines, is pleased to announce that it intends to apply for the Company’s Ordinary Shares to be admitted to trading on AIM and, immediately prior to the Admission to AIM, it intends to withdraw the Company’s Ordinary Shares from trading on PLUS.
